Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations is a phase 3 interventional study registered as NCT07185997 by ArriVent BioPharma, Inc., with 480 participants planned, started 2025-12-17 and due to reach its primary completion in 2029-02. Interventions recorded: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice. Conditions listed: Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing. No results are recorded here; the registry entry is the source.